Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Bücher
Zeitschriften
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
SLX-Digitalkonferenz: Zukunftswerkstatt 2024

Mehr Umsatz mit Top-Kontakten

Am 7. Mai erfahren Sie, wie Vertriebsteams Leadgenerierung, Leadnurturing und Leadstrategien effizient steuern können.
Erweiterte Suche
Anmelden
nach oben
Journal of Nanoparticle Research
Erschienen in: Journal of Nanoparticle Research 12/2022

01.12.2022 | Research paper

AS1411 aptamer improves therapeutic efficacy of PEGylated nanoliposomes loaded with gefitinib in the mice bearing CT26 colon carcinoma

Erschienen in: Journal of Nanoparticle Research | Ausgabe 12/2022

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

In this work, a tumor-targeting liposome containing anti-nucleolin aptamer AS1411 (Apt-Lip-GEF) was developed to deliver gefitinib (GEF) for the treatment of colon cancer. The prepared liposomes were characterized using their morphological properties, size dispersity, zeta potential, encapsulation efficiency, and release properties. The anti-tumor effects of Lip-GEF and Apt-Lip-GEF were measured using cytotoxicity and apoptosis-induced and quantitative real-time PCR. Furthermore, in vivo experiments were evaluated in BALB/c mice bearing CT26 colon carcinoma. Binding of AS1411 to the surface of liposomes was confirmed by gel electrophoresis. The encapsulation efficiency of the Lip-GEF and Apt-Lip-GEF obtained 91 ± 7.1% and 86 ± 5.4%, respectively, and the in vitro release of GEF from both formulations was at acceptable range. Fluorescence microscopy and flow cytometry confirmed the enhanced cellular uptake of AS1411-targeted liposomes in the CT26 cells. Cytotoxicity assay indicated that Apt-Lip-GEF had higher anti-proliferative activity than CT26 cells as positive nucleolin compared to HEK293 as negative nucleolin. At equal concentrations (98 µM), Apt-Lip-GEF was more successful than Lip-GEF in causing apoptosis and cell necrosis. The upregulation of BAX and the downregulation of PIK and AKT as well as BCL2 were observed after treatment with Apt-Lip-GEF in CT26 cells, using qRT-PCR analysis. In cancer model mice, treatment with Apt-Lip-GEF compared with free GEF showed a significant reduction in tumor growth; moreover, the lowest rates of weight change were observed in Apt-Lip-GEF group. Modified nanoliposome acts as a successful delivery system for gefitinib and has high potential for the treatment of colorectal cancer.

Graphical Abstract

Vorheriger Artikel Preparation of nano-ZrB2 powder by Ca liquid assisted boronation reaction between ZrC and B4C
Nächster Artikel Modeling the lattice expansion and contraction of nanocrystals in different interface environments

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Jetzt informieren
Literatur
1.
Siegel RL, Miller KD, Fuchs HE et al (2021) Cancer statistics, 2021. CA: Cancer J Clin 71(1):7–33
2.
Hatami A, Heydarinasab A, Akbarzadehkhiyavi A et al (2021) An introduction to nanotechnology and drug delivery. Chem Methodologies 5(2):153–165
3.
Molaei P, Mahaki H, Manoochehri H, et al (2022) Binding sites of anticancer drugs on human serum albumin (HSA): a review. Protein Pept Lett
4.
Manoochehri H, Asadi S, Tanzadehpanah H et al (2021) CDC25A is strongly associated with colorectal cancer stem cells and poor clinical outcome of patients. Gene Reports 25:101415CrossRef
5.
Tanzadehpanah H, Mahaki H, Moghadam NH et al (2019) Binding site identification of anticancer drug gefitinib to HSA and DNA in the presence of five different probes. J Biomol Struct Dyn 37(4):823–836CrossRef
6.
Moghadam NH, Salehzadeh S, Rakhtshah J et al (2018) Improving antiproliferative effect of the nevirapine on Hela cells by loading onto chitosan coated magnetic nanoparticles as a fully biocompatible nano drug carrier. Int J Biol Macromol 118:1220–1228CrossRef
7.
Tanzadehpanah H, Mahaki H, Moradi M et al (2018) Human serum albumin binding and synergistic effects of gefitinib in combination with regorafenib on colorectal cancer cell lines. Color Cancer 7(2):CRC03CrossRef
8.
Bahmani A, Tanzadehpanah H, Hosseinpour Moghadam N et al (2021) Introducing a pyrazolopyrimidine as a multi-tyrosine kinase inhibitor, using multi-QSAR and docking methods. Mol Diversity 25(2):949–965CrossRef
9.
Rawluk J, Waller CF (2018) Gefitinib. Small molecules in oncology. 235–246
10.
Thierry B (2009) Drug nanocarriers and functional nanoparticles: applications in cancer therapy. Curr Drug Deliv 6(4):391–403CrossRef
11.
Mozafari M (2010) Nanoliposomes: preparation and analysis. Springer, Liposomes, pp 29–50CrossRef
12.
Huang D, Sun L, Huang L et al (2021) Nanodrug delivery systems modulate tumor vessels to increase the enhanced permeability and retention effect. Journal of Personalized Medicine 11(2):124CrossRef
13.
Han J, Gao L, Wang J et al (2020) Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy. J Cancer 11(23):6902CrossRef
14.
Pei X, Zhang J, Liu J (2014) Clinical applications of nucleic acid aptamers in cancer. Mol Clin Oncol 2(3):341–348CrossRef
15.
Xiang D, Shigdar S, Qiao G et al (2015) Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. Theranostics 5(1):23CrossRef
16.
Yazdian-Robati R, Bayat P, Oroojalian F et al (2020) Therapeutic applications of AS1411 aptamer, an update review. Int J Biol Macromol 155:1420–1431CrossRef
17.
Manoochehri H, Jalali A, Tanzadehpanah H, et al (2022) Aptamer-conjugated nanoliposomes containing COL1A1 siRNA sensitize CRC cells to conventional chemotherapeutic drugs. Colloids Surf B Biointerfaces :112714
18.
Chen Z, Xu X (2016) Roles of nucleolin: focus on cancer and anti-cancer therapy. Saudi Med J 37(12):1312CrossRef
19.
Farahbakhsh Z, Zamani MR, Rafienia M et al (2020) In silico activity of AS1411 aptamer against nucleolin of cancer cells. Iranian J Blood Cancer 12(3):95–100
20.
Bates PJ, Laber DA, Miller DM et al (2009) Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86(3):151–164CrossRef
21.
Rohilla S, Awasthi R, Mehta M et al (2022) Preparation and evaluation of gefitinib containing nanoliposomal formulation for lung cancer therapy. BioNanoScience 12(1):241–255CrossRef
22.
Hu Y, Zhang J, Hu H et al (2020) Gefitinib encapsulation based on nano-liposomes for enhancing the curative effect of lung cancer. Cell Cycle 19(24):3581–3594CrossRef
23.
Tanzadehpanah H, Bahmani A, Hosseinpour Moghadam N et al (2021) Synthesis, anticancer activity, and β-lactoglobulin binding interactions of multitargeted kinase inhibitor sorafenib tosylate (SORt) using spectroscopic and molecular modelling approaches. Luminescence 36(1):117–128CrossRef
24.
Zhou X, Yung B, Huang Y et al (2012) Novel liposomal gefitinib (L-GEF) formulations. Anticancer Res 32(7):2919–2923
25.
Afshar S, Pashaki AS, Najafi R et al (2020) Cross-resistance of acquired radioresistant colorectal cancer cell line to gefitinib and regorafenib. Iranian J Med Sci 45(1):50
26.
Zhang Q, Li R, Chen X et al (2017) Effect of weekly or daily dosing regimen of gefitinib in mouse models of lung cancer. Oncotarget 8(42):72447CrossRef
27.
Moradi M, Najafi R, Amini R et al (2019) Remarkable apoptotic pathway of hemiscorpius lepturus scorpion venom on CT26 cell line. Cell Biol Toxicol 35(4):373–385CrossRef
28.
Mahaki H, Jabarivasal N, Sardarian K et al (2019) The effects of extremely low-frequency electromagnetic fields on c-Maf, STAT6, and RORα expressions in spleen and thymus of rat. Electromagn Biol Med 38(2):177–183CrossRef
29.
Duan S, Yu Y, Lai C et al (2018) Vincristine-loaded and sgc8-modified liposome as a potential targeted drug delivery system for treating acute lymphoblastic leukemia. J Biomed Nanotechnol 14(5):910–921CrossRef
30.
Li L, Hou J, Liu X et al (2014) Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials 35(12):3840–3850CrossRef
31.
Liao Z-X, Chuang E-Y, Lin C-C et al (2015) An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance. J Control Release 208:42–51CrossRef
32.
Moosavian SA, Abnous K, Akhtari J et al (2018) 5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells. Artif Cells, Nanomed Biotechnol 46(8):2054–2065
33.
Hernández-Esquivel R-A, Navarro-Tovar G, Zárate-Hernández E, et al (2021) Solid lipid nanoparticles (SLN). Nanocomposite materials for biomedical and energy storage applications: IntechOpen
34.
Abdullah JAA, Jiménez-Rosado M, Perez-Puyana V et al (2022) Green synthesis of FexOy nanoparticles with potential antioxidant properties. Nanomaterials 12(14):2449CrossRef
35.
Torchilin V (2011) Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63(3):131–135CrossRef
36.
Abdullah JAA, Jiménez-Rosado M, Benítez JJ et al (2022) Biopolymer-based films reinforced with FexOy-nanoparticles Polymers 14(21):4487
37.
Satapathy S, Patro CS (2022) Solid lipid nanoparticles for efficient oral delivery of tyrosine kinase inhibitors: a nano targeted cancer drug delivery [review]. Adv Pharm Bull 12(2):298–308
38.
Pourhassan H, Clergeaud G, Hansen AE et al (2017) Revisiting the use of sPLA2-sensitive liposomes in cancer therapy. J Control Release 261:163–173CrossRef
39.
Needham D, Anyarambhatla G, Kong G et al (2000) A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Can Res 60(5):1197–1201
40.
Boratto F, Franco M, Barros A et al (2020) Alpha-tocopheryl succinate improves encapsulation, pH-sensitivity, antitumor activity and reduces toxicity of doxorubicin-loaded liposomes. Eur J Pharm Sci 144:105205CrossRef
41.
Silva JO, Fernandes RS, Lopes SC et al (2016) pH-sensitive, long-circulating liposomes as an alternative tool to deliver doxorubicin into tumors: a feasibility animal study. Mol Imag Biol 18(6):898–904CrossRef
42.
Laginha KM, Verwoert S, Charrois GJ et al (2005) Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 11(19):6944–6949CrossRef
43.
Abdullah Jaa, Jiménez-Rosado M, Guerrero A, et al. Eco-friendly synthesis of ZnO-nanoparticles using Phoenix dactylifera L. polyphenols: physicochemical, microstructural and functional assessment. 2022.
44.
Riahi MM, Sahebkar A, Sadri K et al (2018) Stable and sustained release liposomal formulations of celecoxib: in vitro and in vivo anti-tumor evaluation. Int J Pharm 540(1–2):89–97CrossRef
45.
Su Y, Liu M, Xiong Y et al (2019) Effects of stability of PEGylated micelles on the accelerated blood clearance phenomenon. Drug Deliv Transl Res 9(1):66–75CrossRef
46.
Liu J, Ma H, Wei T et al (2012) CO 2 gas induced drug release from pH-sensitive liposome to circumvent doxorubicin resistant cells. Chem Commun 48(40):4869–4871CrossRef
47.
Zahmatkeshan M, Gheybi F, Rezayat SM et al (2016) Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model. Eur J Pharm Sci 86:125–135CrossRef
48.
Yu Z, Li X, Duan J et al (2020) Targeted treatment of colon cancer with aptamer-guided albumin nanoparticles loaded with docetaxel. Int J Nanomed 15:6737CrossRef
49.
Yao F, An Y, Li X et al (2020) Targeted therapy of colon cancer by aptamer-guided holliday junctions loaded with doxorubicin. Int J Nanomed 15:2119CrossRef
50.
Sheykhhasan M, Ahmadyousefi Y, Seyedebrahimi R, et al (2021) DLX6-AS1: a putative lncRNA candidate in multiple human cancers. Expert Rev Mol Med 23
51.
Mahaki H, Jabarivasal N, Sardarian K et al (2020) Effects of various densities of 50 Hz electromagnetic field on serum IL-9, IL-10, and TNF-α levels. Int J Occup Environ Med 11(1):24CrossRef
52.
Lebedeva IV, Su Z-Z, Sarkar D, et al (Eds) (2003) Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. Seminars in cancer biology: Elsevier
53.
Manoochehri H, Jalali A, Tanzadehpanah H, et al (2021) Identification of key gene targets for sensitizing colorectal cancer to chemoradiation: an integrative network analysis on multiple transcriptomics data. J Gastrointest Cancer :1–20
54.
Dlamini Z, Mbita Z, Zungu M (2004) Genealogy, expression, and molecular mechanisms in apoptosis. Pharmacol Ther 101(1):1–15CrossRef
55.
Zheng L, Gong W, Liang P et al (2014) Effects of AFP-activated PI3K/Akt signaling pathway on cell proliferation of liver cancer. Tumor Biol 35(5):4095–4099CrossRef
56.
Osman G, Rodriguez J, Chan SY et al (2018) PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy. J Control Release 285:35–45CrossRef
57.
Vonarbourg A, Passirani C, Saulnier P et al (2006) Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 27(24):4356–4373CrossRef
Metadaten
Titel
AS1411 aptamer improves therapeutic efficacy of PEGylated nanoliposomes loaded with gefitinib in the mice bearing CT26 colon carcinoma
Publikationsdatum
01.12.2022
Erschienen in
Journal of Nanoparticle Research / Ausgabe 12/2022
Print ISSN: 1388-0764
Elektronische ISSN: 1572-896X
DOI
https://doi.org/10.1007/s11051-022-05630-0

Weitere Artikel der Ausgabe 12/2022

Journal of Nanoparticle Research 12/2022 Zur Ausgabe

Research paper

Vancomycin modified graphene oxide as carriers to load phthalocyanine for synergistic phototherapy of vancomycin-resistant bacteria

Research paper

Gold-capsuled polymeric nanomedicine for synergistic breast cancer photo-chemotherapy

Research paper

Modeling the lattice expansion and contraction of nanocrystals in different interface environments

Research paper

Effect of particle concentration on the flocculation and sedimentation of unstable Al2O3-SiO2/water hybrid nanofluid

Research paper

ZnO/reduced graphene oxide nanocomposite with synergic enhanced gas sensing performance for the effective detection of NO2 at room temperature

Research paper

Sono-assisted synthesis of AgFeO2 nanoparticles for efficient removal of Basic Green-4 dye from aqueous solution

Premium Partner

    Marktübersichten

    Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen. 

    Zur Marktübersicht
    Bildnachweise